Galderma Gets First Biologic To Market With Nemluvio Approval

 
• By Jessica Merrill

Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis. 

Galderma is launching its first biologic drug • Source: Shutterstock

More from Dermatological

More from Therapy Areas